statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 1,140,000 shares, an increase...

Immutep Limited (NASDAQ:IMMP) Short Interest Up 5.6% in March

Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.35 and traded as high as $2.47. Immutep...

Immutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average of $2.35

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immutep announces first clinical data from 90mg dosing of efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who...

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Limited (NASDAQ:IMMP  Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...

Immutep Limited (NASDAQ:IMMP) Short Interest Up 53.4% in January

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing...

Immutep Quarterly Activities Report Q2 FY24

Immutep announces first patient enrolled, dosed in INSIGHT-005 trial

Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company ), a clinical-stage biotechnology company developing novel...

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO  in Metastatic Urothelial Cancer

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.

Watchers	8,915
52-Wk Low	$1.50
52-Wk High	$3.90

Volume	543,609.00
52-Wk High	$3.90
52-Wk Low	$1.50

Period	Estimated	Reported	Surprise	Result
Q4'24	-$0.18	--	--	N/A
Q2'24	-$0.13	--	--	N/A
Q4'23	-$0.15	--	--	N/A
Q2'23	-$0.16	--	--	N/A
Q4'22	-$0.15	-$0.16	-1.58%	MISSED

IMMP Immutep LTD ADR

About

Feed

News

Sentiment

Earnings

Fundamentals